ゲノム編集の決定版ガイド。
メニュー
ホーム 学ぶ ニュース Atlasに聞く
探索する 技術 疾患 治療法 臨床試験 企業 科学者 遺伝子 研究 研究機関
医療を超えて 農業 倫理 投資 世界地図
学ぶ・ツール まずはここから 用語集 A~Z 技術を比較する タイムライン リスト・ランキング AIエージェント ★ 保存済み API
このサイトについて 私たちについて 方法論 データソース 編集方針 お問い合わせ 免責事項

🧭 ガイドビュー
遺伝学が初めてですか? 閲覧しながら、すべての用語をわかりやすく説明します。同じページに、サポートが組み込まれています。

⚡ 専門家の見解
生物学はすでにご存知の方へ。コンテンツだけをすっきりとコンパクトに、余分な説明なしでお届けします。これがデフォルト表示です。

表示言語
ライトモード

倫理 · Human editing

Human embryo research

Editing embryos in the laboratory, without transfer to a uterus, is permitted in some countries and prohibited in others — and it is how the risks of germline editing are actually studied.

How this page is written The Atlas does not take a position on contested ethical questions. Each page sets out the strongest version of the arguments on each side, states what is scientifically settled and what is not, and summarises the law where it exists. Where we think a claim is factually wrong — as opposed to ethically contested — we say so and cite the evidence.

率直な問い

There is a difference between editing an embryo to learn something and editing one to make a baby. The first happens in laboratories under licence in several countries, with embryos destroyed after a limited period and never transferred to a uterus. It is also how researchers discovered that embryo editing is far messier than expected — knowledge that is a central argument against ever doing it reproductively.

Research editing of human embryos without transfer is regulated distinctly from reproductive use. The UK permits it under HFEA licence within the 14-day limit; several countries permit it under national frameworks; others prohibit it entirely. Research has revealed high rates of mosaicism, large on-target deletions and loss of heterozygosity following editing in embryos — findings that materially strengthen the safety case against reproductive use, and that could not have been obtained any other way.

The arguments

支持する意見
  • It is the only way to understand early human development and why so many pregnancies fail.
  • It generates precisely the safety data needed to evaluate germline claims, rather than speculating.
  • Strict licensing with a firm limit and no transfer is a workable and long-established framework.
  • Model organisms diverge from humans at exactly the developmental stages that matter most.
批判的な意見
  • Some hold that an embryo has moral status making research use impermissible regardless of benefit.
  • Permitting research use may make reproductive use more likely over time.
  • The 14-day limit was a pragmatic convention rather than a principled boundary, and pressure to extend it is now real.

Where the science actually stands

Research editing without transfer is legal under licence in several countries and prohibited in others; positions follow national law and values rather than scientific disagreement. The research itself has produced findings — mosaicism, large deletions, loss of heterozygosity — that are central to why reproductive germline editing is not considered safe.

Law and regulation

管轄ポジションツール
United Kingdom Permitted under HFEA licence up to 14 days; transfer to a uterus prohibited Human Fertilisation and Embryology Act
United States No federal funding for research destroying embryos; privately funded research permitted in some states Dickey-Wicker Amendment; state law
Germany Highly restricted Embryonenschutzgesetz
Japan Permitted for research under guidelines; reproductive use prohibited National guidelines

法的助言としてではなく、概要把握のための要約です。法律は変わり、各国での施行内容も異なります。対象となる法域の現行法を必ずご確認ください。

Unresolved questions

  • Whether the 14-day limit should be revised now that culture beyond it is technically possible.
  • How to fund and oversee research that many citizens object to on principle.

Sources